OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) and Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.
Institutional & Insider Ownership
91.0% of OnKure Therapeutics shares are owned by institutional investors. 2.3% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for OnKure Therapeutics and Agios Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OnKure Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
| Agios Pharmaceuticals | 1 | 4 | 6 | 0 | 2.45 |
Profitability
This table compares OnKure Therapeutics and Agios Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OnKure Therapeutics | N/A | -61.02% | -55.99% |
| Agios Pharmaceuticals | -639.84% | -34.11% | -31.66% |
Volatility & Risk
OnKure Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Earnings and Valuation
This table compares OnKure Therapeutics and Agios Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OnKure Therapeutics | N/A | N/A | -$59.52 million | ($4.33) | -0.90 |
| Agios Pharmaceuticals | $66.05 million | 25.02 | -$412.78 million | ($7.25) | -3.83 |
OnKure Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Agios Pharmaceuticals beats OnKure Therapeutics on 7 of the 13 factors compared between the two stocks.
About OnKure Therapeutics
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
